Crohn's Disease and Colitis Trial, Recruiting (NCT07644117)

Crohn's Disease and Colitis Trial, Recruiting NCT07644117 Sponsor: Shmuel Kivity, MD Condition: Crohn's Disease and Colitis

Printed from Voxsanity (voxsanity.com.au) — NCT07644117 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Crohns Disease And Colitis

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have been diagnosed with Inflammatory Bowel Disease (IBD), either Crohn's disease or ulcerative colitis
People who have never previously been treated with a type of medication called anti-TNF therapy
People whose IBD is currently active, meaning symptoms are above a certain level of severity as measured by standard scoring tools used by doctors
People who have blood or stool test results showing signs of active inflammation above certain levels

Who may not be able to join:

People who are unable to give their informed agreement to take part in the study
People who have previously been treated with anti-TNF therapy at any point
People who would be unable to complete all the requirements of the study as set out by the trial team

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Ayal Hirsch, MD, Tel Aviv Sourasky University Medical Center

Phone: +97237772613

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07644117

Sponsor: Shmuel Kivity, MD

Phase: Not Applicable

Status: Recruiting

Condition: Crohn's Disease and Colitis

Trial contact: +97237772613

More information: https://clinicaltrials.gov/study/NCT07644117

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have been diagnosed with Inflammatory Bowel Disease (IBD), either Crohn's disease or ulcerative colitis
People who have never previously been treated with a type of medication called anti-TNF therapy
People whose IBD is currently active, meaning symptoms are above a certain level of severity as measured by standard scoring tools used by doctors
People who have blood or stool test results showing signs of active inflammation above certain levels

Who may not be able to join:

People who are unable to give their informed agreement to take part in the study
People who have previously been treated with anti-TNF therapy at any point
People who would be unable to complete all the requirements of the study as set out by the trial team

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Shmuel Kivity, MD

Registry

ClinicalTrials.gov

Start date

4 January 2025

Est. completion

1 May 2028

Where this trial is recruiting

🇮🇱 Israel

Primary endpoints

Rates of clinical response in UC patients; Rates of clinical response in UC patients; Rates of clinical response in UC patients; Rates of clinical response in CD patients; Rates of clinical response in CD patients; Rates of clinical response in CD patients; Rates of clinical remission for UC; Rates of clinical remission for UC; Rates of clinical remission for UC; Rates of clinical remission for CD; Rates of clinical remission for CD; Rates of clinical remission for CD

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov